Today, we have filed for patent protection for our innovative cancer vaccine technology. In cooperation with the patent attorney office, Potter Clarkson AS, we have submitted our application at the United Kingdom patent office for protection towards the development, manufacturing and sale of ALAVCAN-DC products.
The technology we are protecting can create cancer vaccines quicker and cheaper than standard DC vaccine protocols published to date, while also resulting in 50x higher cytokine secretion compared to reference protocols, during our preliminary laboratory tests.
This marks a milestone for Alv B and brings us one step closer to market and to improving cancer care in dogs and humans globally.
